Skip to content
The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute

Research Projects

The CHOICE Faculty are involved in a wide range of funded and unfunded research projects. They have been at the forefront of creating the next generation of thinkers and leaders in the field of economic evaluations, drug safety, and health care economics. They are known internationally for their work on developing and applying methods to critically assess information needs to improve population health and prioritize research investments given limited budgets. They are collaborating with some of the leading initiatives (e.g. Institute for Clinical and Economic Review (ICER)) in the nation in assessing the value of new interventions.  In addition, the CHOICE Institute has a rich history of working with decision makers, such as patients, physicians, industry and payers, providing expertise, and facilitating collaborations at the regional, national, and global level.

The future of the CHOICE faculty is bright.  The faculty are poised to address many national and global challenges – from continued opportunities to inform national policy, to studying changes to the Affordable Care Act and triple aim health care, guiding WA state to achieve effective universal health insurance coverage,  to determining value and guiding best practices with the increase in personalized medicines, to understanding how human behavior affects medication adherence and clinical results, to the rise of technology in healthcare, to better ensuring favorable benefit-risk of medicines and other health technologies, to growing the international platform and linking with the important work done through the Global Medicines Program.

A list of active research projects are listed here. Specific projects that have generated research resources are also highlighted under specific tabs on the right.

Aasthaa Bansal

  • PI: Personalized Risk-Adaptive Surveillance Strategies in Cancer (PRAISE); NIH (R37), 07/01/2018-06/30/2023

Douglas Barthold

  • PI: NIA (K01) “Long-term effects of today’s medical care access policies on the future burden of Alzheimer’s disease and related dementias,” 2022-2026
  • PI: PhRMA Foundation “The role of mild cognitive impairment (MCI) and Alzheimer’s disease and related dementias (ADRD) in the utilization of high and low value healthcare,” 2021-2023
  • Co-I: NIH (R01) “Acceptability of sustained-release antiretrovirals for treatment in the US and sub-Saharan Africa,” 2019-2024
  • Co-I:  NIA(U19) “Adult Changes in Thought (ACT) Research Program (Renewal),” 2021-2026

Anirban Basu

  • PI: Empowering the Annual Health Econometrics Workshop; AHRQ, 2017-2019
  • PI: Value of Information Methods for NHLBI Trials; NHLBI (R01), 4/15/2015 – 3/31/2019
  • PI: Cure Sickle Cell, Model for Economic Analysis of Sickle Cell (CureSC: MEASURE); NHLBI, 07/01/2019 – 06/30/2022
  • Co-PI (PI: Coleman, Kaiser Permanente): Effectiveness of Gastric Sleeve vs. Gastric Bypass for Cardiovascular Disease; NHLBI R01, 2016-2019
  • Co-I: (PI: Carlson) ICER Economic Modeling; ICER, 1/2020-12/2021

Josh Carlson

  • PI: ICER Economic Modeling; ICER, 1/2020-12/2021
  • PI: (subcontract) BEAT MS clinical trial; Benaroya Research Institute at Virginia Mason and NIAID, 2/2019 – 2/2021
  • PI: (subcontract) Oncology Value-based Pricing Project; Fred Hutchinson Cancer Research Center and BMS, 1/2019 – 4/2020

Beth Devine

  • PI: Customizing Value-based Methods to Prioritize Implementation of Pharmacogenomic Clinical Decision Support for Learning Health Systems. (PRECISE-VALUE); AHRQ, 2019-2021
  • Site PI: Assistant Director: Pacific Northwest Evidence-based Practice Center (EPC) VI; AHRQ, 2019-2024
  • Lead Co-I (PI: Goddard, Kaiser Permanente Center for Health Research): Cancer Health Assessments Reaching Many (CHARM); NHGRI, 2018-2021
  • Lead Co-I (PI: Czerniecki, VA Center for Limb Loss and Mobility): Improving Dysvascular Amputee Outcomes by Enhancing Shared Decision Making (AMP-DECIDE); VAHSR&D, 2018-2022
  • Lead Co-I (PI: Basu): Cure Sickle Cell, Model for Economic Analysis of Sickle Cell (CureSC: MEASURE); NHLBI, 2019-2022
  • PI: UW-Allergan Post-Doctoral Fellowship (Training Grant); Allergan Pharmaceuticals, 2012 – 2023
  • Lead Co-I (PI: Veenstra): Payer Demand for RWE in HTA: A DCE, Health Technology Fund, UW Outcomes Corporate Advisory Board, 2018-2020
  • Key personnel (Site PI: Gray): US Deprescribing Research Network; NIA, 2019-2021
  • Co-I (PI: Bowen): Randomized trial of genetic testing methods for primary care patients (PICNIC); NHGRI, 2020-2024
  • Associate Director: UW Health Services Research T32; AHRQ, 2018-2023
  • Faculty Mentor: UW Biomedical and Health Informatics T32; NLM, 2017-2022
  • Faculty Mentor: UW Developing Data-Driven Cancer Researchers T32; NCI, 2016-2021

Louis Garrison, Jr. 

  • Principal Mentor, UW-Pfizer Post-Doctoral Fellowship, 2016-2018.
  • Co-Inv. (PI-Chung) University of Nairobi HIV Capacity Building Fellowship. USAID, 2014-2018

Ryan Hansen

  • Co-I: National Association of Chain Drug Stores (NACDS) Foundation: Gaps in Care (Community Pharmacy Increasing Statin Utilization for People with Diabetes)
  • Team Lead: Institute for Clinical and Economic Review: Comparative Value Modeling Team
  • Co-I: National Institutes of Health (NIH): Pilot Study of a Community-Pharmacy Model to Expand Access to Medications to Treat and Prevent Hepatitis C, Opioid Use Disorders, Overdose and HIV Among Persons Who Inject Drugs
  • Co-I: Washington State Department of Health (sub from CDC): Support ACT Prescription Drug Monitoring Program
  • Co-I: Cystic Fibrosis Foundation: Cost Effectiveness Analysis and Comparative Effectiveness Research of STOP2

Scott Ramsey

  • Ramsey Sub-PI (Main PI Charles Blanke, OSHU), Ancillary Study to Evaluate Patient and Physician Knowledge, Attitudes, and Preferences Related to Return of Genomic Results in the SWOG 1400 (S1400) Clinical Trial. Project Dates 8/2016-2/2018

Andy Stergachis

  • PI of UW Subcontract (Main PI: Aboagye-Nyame) Medicines, Technologies, and Pharmaceutical Services (MTaPS); USAID
  • PI of UW Subcontract (Main PI: Buekens).  Landscape Analysis:  Sentinel Site Readiness for Maternal Immunization Active Safety Surveillance in LMIC; Bill & Melinda Gates Foundation
  • Co-I: (PI: Murray) Mapping and Monitoring the Global Burden of Antimicrobial Resistance; Fleming Fund, Wellcome Trust, BMGF
  • Co-I: (PI: Bacci) Community Pharmacist Population Health Management of People Living with Epilepsy; UCB Pharma
  • Co-I: (PI: Baeten) Pharmacy Delivery to Expand the Reach of PrEP in Kenya; NIH-NIMH (R34)
  • Co-I: (PI: Ho) Washington Entrepreneurial Research Evaluation and Commercialization Hub; NIH/NHLBI
  • Co-I: (PI: Farquhar) Health-Professional Education Partnership Initiative (HEPI) – Kenya; NIH/Fogarty

Sean Sullivan

  • Consortium PI: Comparative Effectiveness of CSF; A Pragmatic Trial to Improve Colony Stimulating Factor Use in Cancer; Fred Hutchinson Cancer Research Center, 2016-2021
  • PI, PCOR K12: Mentored Career Development Program in Patient-Centered Outcomes Research; AHRQ, 2012 – 2019
  • Co-Director: Pacific Northwest Evidence-Based Practice Center; AHRQ, 2012 – 2017
  • Co-Investigator: PTN ON (PI David Flum) Practice Transformation Network; CMS, 2017-2018

David Veenstra

  • PI: Fellowships in HEOR. Genentech, Inc., 07/01/2018 – 06/30/2021
  • Site PI: Rational Integration of clinical SEquencing (RISE); Vanderbilt University Medical Center, 09/05/2017 – 07/31/2021
  • Co-I: (PI: Thummel) Program on Genetic and Dietary Predictors of Drug Response in Rural and AI/AN; NIH, 08/01/2017-07/31/2021
  • Co-I: (PI: Bansal) Personalized Risk-Adaptive Surveillance strategies in Cancer (PRAISE); NIH, 07/01/2018-06/30/2023
  • Co-I: (PI: Devine) Cancer Health Assessment Reaching Many (CHARM); Kaiser Foundation Research Institute, 06/01/2018 – 05/31/2021
  • Co-I: (PI: Jarvik) Evolving Our Partnership: The CSER2 Centralized Support Coordinating Center (CSER2 Coord Center); NIH, 04/01/2013 – 06/30/2021
  • Co-I: (PI: Jarvik) The Electronic Medical Records and Genomics (eMERGE) Network, Phase III; Kaiser Foundation Health Plan of WA, 04/25/2019 – 03/31/2020